Bombay HC on Pharma Trademarks: The Bare Possibility Test
In Indian pharmaceutical trademark law, the 'bare possibility' test is the primary threshold for determining deceptive similarity. Because patient safety outweighs commercial interest, courts do not require proof of actual confusion or probability; they intervene if there is even a remote risk of error during prescription or dispensing. Applying the anti-dissection rule, courts assess marks as a whole rather than by syllable, ensuring that confusingly similar drug names are restrained even when they belong to different therapeutic classes or contain different active ingredients.